Pauza Charles David 4

What Happened
Charles Pauza, Chief Science Officer — Virology at Traws Pharma (TRAW), was granted 97,000 derivative awards on 2026-07-09. The Form 4 reports the award at $0.00 (no cash purchase) and classifies the grant as a derivative (stock options). The filing does not state an exercise price or immediate dollar value and there was no exercise or sale reported.

Key Details

• Transaction date: 2026-07-09; Form 4 filed: 2026-07-16 (filed late relative to the 2-business-day rule).
• Security: 97,000 derivative awards (stock options) reported as an Award/Grant (code A). Reported acquisition price: $0.00.
• Vesting: Per footnote, the options vest 100% on the first anniversary of the grant date.
• Approval: Award was granted by the issuer’s compensation committee composed of independent directors (per footnote).
• Shares owned after transaction: Not specified in this filing.
• No indication of exercise, sale, tax withholding, or 10b5-1 plan in this filing.

Context
This is a grant of stock options (a compensation award), not an open‑market purchase or sale. Such awards typically provide potential upside if the stock rises and generally vest over time (here, fully after one year). Because the exercise price and other option terms are not disclosed in the Form 4 excerpt, you cannot infer immediate monetary value. The filing was submitted beyond the standard two-business-day reporting window, which is a timeliness violation noted on the Form 4.